Enanta outlines 2026 milestones for RSV and immunology programs

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) announced updates on its research and development programs and outlined key milestones for 2026, according to a company statement.

The biotechnology company is continuing Phase 3 enabling activities for zelicapavir, its oral RSV N-protein inhibitor, following positive Phase 2b results. The company plans to align with the FDA on an adult Phase 3 trial design in the second quarter of 2026 and prepare for a Phase 3 study in high-risk adults in the second half of 2026.

Enanta expanded its immunology pipeline with a new discovery program focused on MRGPRX2 inhibition for chronic spontaneous urticaria and other mast cell-driven diseases. The company expects to select a development candidate for this program in the second half of 2026.

The company plans to file an Investigational New Drug application for EDP-978, its oral KIT inhibitor clinical candidate, in the first quarter of 2026 and report Phase 1 data in the fourth quarter. For EPS-3903, its oral STAT6 inhibitor development candidate, Enanta targets an IND filing in the second half of 2026.

In August 2025, Enanta filed a patent infringement action in the European Union's Unified Patent Court against Pfizer Inc. regarding European Patent No. EP 4 051 265 in connection with Paxlovid sales. The company expects to provide an update on this litigation in the second half of 2026.

Enanta reported having cash runway expected to fund operations into fiscal 2029, supported by continuing retained royalties. The company will present its 2026 outlook at the J.P. Morgan Healthcare Conference on January 14 at 3:00 PM PT.

You May Also Be Interested In

• McEwen Copper seeks $1.6b in equity financing for Los Azules - Bloomberg
• SEC proposes rules to create regime for some crypto contracts
• U.S. oil producers expected to sign with PDVSA Tuesday - Politico